389 related articles for article (PubMed ID: 12579279)
1. External beam radiotherapy in bone metastatic prostate cancer: impact on patients' pain relief and quality of life.
Di Lorenzo G; Autorino R; Ciardiello F; Raben D; Bianco C; Troiani T; Pizza C; De Laurentiis M; Pensabene M; D'Armiento M; Bianco AR; De Placido S
Oncol Rep; 2003; 10(2):399-404. PubMed ID: 12579279
[TBL] [Abstract][Full Text] [Related]
2. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported lower urinary tract symptoms, urinary incontinence, and quality of life after external beam radiotherapy for localized prostate cancer--15 years' follow-up. A comparison with age-matched controls.
Fransson P
Acta Oncol; 2008; 47(5):852-61. PubMed ID: 17899451
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes.
Robinson JW; Donnelly BJ; Siever JE; Saliken JC; Ernst SD; Rewcastle JC; Trpkov K; Lau H; Scott C; Thomas B
Cancer; 2009 Oct; 115(20):4695-704. PubMed ID: 19691092
[TBL] [Abstract][Full Text] [Related]
5. Quality of life in patients with skeletal metastases of prostate cancer and status prior to start of endocrine therapy: results from the Scandinavian Prostate Cancer Group Study 5.
Jønler M; Nielsen OS; Groenvold M; Hedlund PO; Damber L; Hedelin H; Waldén M;
Scand J Urol Nephrol; 2005; 39(1):42-8. PubMed ID: 15764270
[TBL] [Abstract][Full Text] [Related]
6. Half body irradiation of patients with multiple bone metastases: a phase II trial.
Berg RS; Yilmaz MK; Høyer M; Keldsen N; Nielsen OS; Ewertz M
Acta Oncol; 2009; 48(4):556-61. PubMed ID: 18979285
[TBL] [Abstract][Full Text] [Related]
7. Potency preservation following conformal radiotherapy for localized prostate cancer: impact of neoadjuvant androgen blockade, treatment technique, and patient-related factors.
Mantz CA; Nautiyal J; Awan A; Kopnick M; Ray P; Kandel G; Niederberger C; Ignacio L; Dawson E; Fields R; Weichselbaum R; Vijayakumar S
Cancer J Sci Am; 1999; 5(4):230-6. PubMed ID: 10439169
[TBL] [Abstract][Full Text] [Related]
8. Colorectal complications of external beam radiation versus brachytherapy for prostate cancer.
Lesperance RN; Kjorstadt RJ; Halligan JB; Steele SR
Am J Surg; 2008 May; 195(5):616-20; discussion 620. PubMed ID: 18374892
[TBL] [Abstract][Full Text] [Related]
9. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
Wong WW; Schild SE; Vora SA; Halyard MY
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
[TBL] [Abstract][Full Text] [Related]
10. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
11. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases.
Hartsell WF; Scott CB; Bruner DW; Scarantino CW; Ivker RA; Roach M; Suh JH; Demas WF; Movsas B; Petersen IA; Konski AA; Cleeland CS; Janjan NA; DeSilvio M
J Natl Cancer Inst; 2005 Jun; 97(11):798-804. PubMed ID: 15928300
[TBL] [Abstract][Full Text] [Related]
13. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
14. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
15. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
Park KU
Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma.
Oehler-Jänne C; Seifert B; Lütolf UM; Studer G; Glanzmann C; Ciernik IF
Brachytherapy; 2007; 6(3):218-26. PubMed ID: 17681244
[TBL] [Abstract][Full Text] [Related]
18. 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer.
Martin T; Röddiger S; Kurek R; Dannenberg T; Eckart O; Kolotas C; Heyd R; Rogge B; Baltas D; Tunn U; Zamboglou N
Radiother Oncol; 2004 Apr; 71(1):35-41. PubMed ID: 15066294
[TBL] [Abstract][Full Text] [Related]
19. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
Akimoto T; Kitamoto Y; Saito J; Harashima K; Nakano T; Ito K; Yamamoto T; Kurokawa K; Yamanaka H; Takahashi M; Mitsuhashi N; Niibe H
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):372-9. PubMed ID: 15145150
[TBL] [Abstract][Full Text] [Related]
20. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
